More Imugene Ltd news
Imugene LtdASX: IMU

S&P DJI Announces December 2021 Quarterly Rebalance

Dec 3, 2021 at 6:21 AM EST · Issued by Imugene Ltd

Filed with ASX · Dec 3, 2021 at 6:21 AM EST · 3 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-december-2021-quarterly-rebalance-12

Imugene Ltd on 6ix

Story so far

  • S&P DJI Announces September 2021 Quarterly RebalanceSep 3, 2021
  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021

Earlier from Imugene

  • Clinical Trial Supply Agreement with Merck KGaA and PfizerNov 15, 2021
  • Investor Presentation Imugene Eureka TherapeuticsOct 31, 2021
  • First patient dosed in Phase I clinical trial of CHECKvaccOct 20, 2021
  • Imugene HER-Vaxx Immunotherapy Patent Granted in JapanSep 21, 2021
  • S&P DJI Announces September 2021 Quarterly RebalanceSep 3, 2021

Later from Imugene

  • Update on Clinical Trial of Oncolytic Virotherapy CHECKvaccDec 6, 2021
  • FDA IND approval for the phase 2 clinical trial of HER-VaxxDec 12, 2021
  • Imugene completes Phase 1a trial of immunotherapy PD1-VaxxJan 3, 2022
  • South Korea HERVaxx Patent GrantJan 5, 2022
  • Imugene Receives $6.54 million R&D Tax IncentiveJan 6, 2022
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer